RAD 2025 Conference: Abstracts to Watch

Few medical subfields have witnessed as much of a transformation in both therapeutic innovation and patient-centered care as dermatology, and this is especially true in the realm of atopic dermatitis. While the inflammatory condition was once managed using limited topical agents and immunosuppressants, atopic dermatitis treatment has entered an era involving a deeper understanding of immune pathways and molecular targets.

With the growing biologics pipeline, there is a rapidly evolving treatment landscape. At the forefront of this evolution is the Revolutionizing Atopic Dermatitis (RAD) Annual Meeting, a scientific forum in which leading dermatologists and health care providers convene and unveil late-breaking data, network with one another, highlight new disease insights, and present a variety of talks on emerging therapies and new research.

The RAD meeting—taking place in Nashville from June 6-7, 2025—will feature a variety of new abstracts, highlighting research in the dermatology space for the benefit of RAD conference attendees. In this list, the HCPLive editorial team highlights a series of abstracts worth looking out for during the meeting:

5 Abstracts in Pediatric Dermatology:

1. Improvement in Atopic Dermatitis Signs and Symptoms With Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: Results From the 52-Week Phase 3 INTEGUMENT-OLE Trial in Patients Aged ≥2 Years
2. Growth Improvement in Children Aged 6 to 11 Years with Severe Atopic Dermatitis Treated with Dupilumab Irrespective of Cumulative TCS Use
3. Maintenance of Disease Control Over 2 Years in Patients With Atopic Dermatitis Treated With Dupilumab
4. Social Determinants in Early Childhood Atopic Dermatitis: Insights from a Medicaid-Eligible Cohort in Rochester, NY
5. Disease and family burden of moderate-to-severe atopic dermatitis in children aged <6 years: results from the PEDISTAD registry

5 Abstracts in Skin of Color:

1. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: Final 24-Week results from the phase 3b, open-label ADmirable study
2. Improvements in patient-reported outcomes and quality of life with dupilumab monotherapy in patients with skin of color and moderate-to-severe atopic dermatitis
3. Total IgE Reduction with Dupilumab in Pediatric Moderate-to-Severe Atopic Dermatitis: 1.5-Year Follow-up Data
4. Post-inflammatory pigmentation reductions in patients with atopic dermatitis with skin of color treated with dupilumab monotherapy
5. Dupilumab monotherapy in patients with skin of color and moderate-to-severe atopic dermatitis: results from a phase 4, open-label study

5 Additional Abstracts of Note:

1. Evaluating the Risk of New-Onset Bullous Pemphigoid Following Dupilumab Treatment for Atopic Dermatitis
2. Application of real-world effectiveness of upadacitinib for atopic dermatitis in adult and adolescent patients to minimal disease activity criteria: a retrospective multicenter analysis of week 16±8 data
3. A Real-World Multi-center Retrospective Safety Analysis of Ruxolitinib 1.5% cream in Combination with Systemic Therapies for the Management of Atopic Dermatitis
4. Dupilumab Is Efficacious in Patients Above and Below 65 Years Old With Prurigo Nodularis: Pooled Results From Two Phase 3 Trials (LIBERTY-PN PRIME and PRIME2)
5. Patients with Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)

For more information on new data and on-site interviews with trial investigators, view our latest conference coverage.